Evidence map›Paper›PMID 30775247›Full record

ReviewAsian journal of urology2019

Current strategies for targeting the activity of androgen receptor variants.

Cameron M Armstrong, Allen C Gao

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asian journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Small-molecule disruption of androgen receptor-dependent chromatin clusters.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Review
  6. Modulating the Activity of Androgen Receptor for Treating Breast Cancer.International journal of molecular sciences · 2022
    Review
  7. Constitutively Active Androgen Receptor in Hepatocellular Carcinoma.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Cameron M ArmstrongDepartment of Urology, University of California, Davis, Sacramento, CA, USA.
Allen C GaoDepartment of Urology, University of California, Davis, Sacramento, CA, USA.
University of California, Davis · USVA Northern California Health Care System · US

Funding

Novel roles of microRNA in androgen receptor signalingR01CA168601 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GAO, ALLEN C. · 2013 to 2017
$1.5M
(PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resistR21CA179970 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GAO, ALLEN C. · 2013 to 2014
$363k
The role of p52 in prostate cancerI01BX002653 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI GAO, ALLEN C. · 2014 to 2017
–
BLRD VA I01 BX002653NCI NIH HHS R01 CA168601NCI NIH HHS R21 CA179970
6 · The paper itself

Abstract

Current therapies for advanced prostate cancer, such as enzalutamide and abiraterone, focus on inhibiting androgen receptor (AR) activity and reducing downstream signaling pathways to inhibit tumor growth. Unfortunately, cancer cells are very adaptable and, over time, these cells develop mechanisms by which they can circumvent therapeutics. One of the many mechanisms that have been discovered is the generation of AR variants. These variants are generated through alternative splicing of the full length AR and often lack the ligand binding domain. This leads to forms of the AR that are constitutively active that continue to promote prostate cancer cell growth even in the absence of ligand. The high prevalence of AR variants and their role in disease progression have prompted a number of studies investigating ways to inhibited AR variant expression and activity. Among these are the anti-helminthic drug, niclosamide, which selectively promotes degradation of AR variants over full length AR and re-sensitizes anti-androgen resistant prostate cancer cells to treatment with enzalutamide and abiraterone. Other AR variant targeting mechanisms include interfering with AR variant co-activators and the development of drugs that bind to the DNA or N-terminal AR domains, which are retained in most AR variants. The clinical efficacy of treating prostate cancer by targeting AR variants is under investigation in several clinical trials. In this review, we provide an overview of the most relevant AR variants and discuss current AR variant targeting strategies.

Indexed as

Androgen receptor variantsDrug resistanceProstate cancer

Identifiers

PMID30775247
PMCPMC6363599
OpenAlexW2893952967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.